Patent: 7,919,264
✉ Email this page to a colleague
Summary for Patent: 7,919,264
Title: | Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers |
Abstract: | The invention provides a method for determining the efficacy of a TNF.alpha. inhibitor, such as a TNF.alpha. antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker. |
Inventor(s): | Maksymowych; Walter P. (Edmonton, CA), Wong; Robert L. (Basking Ridge, NJ) |
Assignee: | Abbott Biotechnology Ltd. (Hamilton, BM) |
Application Number: | 11/591,241 |
Patent Claims: | see list of patent claims |
Details for Patent 7,919,264
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 09/23/2014 | ⤷ Try a Trial | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 11/23/2015 | ⤷ Try a Trial | 2021-03-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |